Dopamine in schizophrenia: a review and reconceptualization

Back to table of contents Previous article Next article No AccessDopamine in schizophrenia: a review and reconceptualizationPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.148.11.1474AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractOBJECTIVE: The initial hypothesis that schizophrenia is a manifestation of hyperdopaminergia has recently been faulted. However, several new findings suggest that abnormal, although not necessarily excessive, dopamine activity is an important factor in schizophrenia. The authors discuss these findings and their implications. METHOD: All published studies regarding dopamine and schizophrenia and all studies on the role of dopamine in cognition were reviewed. Attention has focused on post-mortem studies, positron emission tomography, neuroleptic drug actions, plasma levels of the dopamine metabolite homovanillic acid (HVA), and cerebral blood flow. RESULTS: Evidence, particularly from intracellular recording studies in animals and plasma HVA measurements, suggests that neuroleptics act by reducing dopamine activity in mesolimbic dopamine neurons. Post-mortem studies have shown high dopamine and HVA concentrations in various subcortical brain regions and greater than normal dopamine receptor densities in the brains of schizophrenic patients. On the other hand, the negative/deficit symptom complex of schizophrenia may be associated with low dopamine activity in the prefrontal cortex. Recent animal and human studies suggest that prefrontal dopamine neurons inhibit subcortical dopamine activity. The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity (causing deficit symptoms) leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms). CONCLUSIONS: The possible co-occurrence of high and low dopamine activity in schizophrenia has implications for the conceptualization of dopamine's role in schizophrenia. It would explain the concurrent presence of negative and positive symptoms. This hypothesis is testable and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byEvaluation of cognitive insight, social functionality, and coping attitudes of patients diagnosed with schizophrenia being followed-up in a community mental health centerArchives of Psychiatric Nursing, Vol. 43The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia15 November 2022 | Neuropsychopharmacology, Vol. 48, No. 4The substantia nigra in the pathology of schizophrenia: A review on post-mortem and molecular imaging findingsEuropean Neuropsychopharmacology, Vol. 68Porous Nitrogen-Doped Crumpled Graphene Nanoparticles: A Metal-Free Nanozyme for Selective Detection of Dopamine in Aqueous Medium and Human Serum24 January 2023 | ACS Applied Nano Materials, Vol. 6, No. 3Integrative Roles of Dopamine Pathway and Calcium Channels Reveal a Link between Schizophrenia and Opioid Use Disorder17 February 2023 | International Journal of Molecular Sciences, Vol. 24, No. 4Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment23 January 2023 | Molecular Psychiatry, Vol. 125Altered static and dynamic functional connectivity of habenula in first-episode, drug-naïve schizophrenia patients, and their association with symptoms including hallucination and anxiety19 January 2023 | Frontiers in Psychiatry, Vol. 14Coreactant-free polyfluorene nanoparticles for the electrochemiluminescence quantitative analysis of dopamine and norepinephrine1 January 2023 | Sensors & Diagnostics, Vol. 2, No. 1Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders16 September 2022 | Medicinal Research Reviews, Vol. 43, No. 1Understanding the Chemical Interactions in the Brain of Schizophrenia Patients1 January 2023A Novel Microfluidic-Based OMC-PEDOT-PSS Composite Electrochemical Sensor for Continuous Dopamine Monitoring31 December 2022 | Biosensors, Vol. 13, No. 1Metabotropic glutamate receptors and cognition: From underlying plasticity and neuroprotection to cognitive disorders and therapeutic targetsBiological hypotheses, risk factors, and biomarkers of schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 120The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia7 November 2022 | Translational Psychiatry, Vol. 12, No. 1Language abnormalities in schizophrenia: binding core symptoms through contemporary empirical evidence12 November 2022 | Schizophrenia, Vol. 8, No. 1Social anhedonia as a Disrupted-in-Schizophrenia 1-dependent phenotype17 June 2022 | Scientific Reports, Vol. 12, No. 1Prefrontal and Striatal Dopamine Release Are Inversely Correlated in SchizophreniaBiological Psychiatry, Vol. 92, No. 10The impact of childhood trauma and daily life experiences on emotional and psychotic symptom intensity in psychosis: An experience sampling studyPsychiatry Research, Vol. 317Schizophrenia, Bipolar and Major Depressive Disorders: Overview of Clinical Features, Neurotransmitter Alterations, Pharmacological Interventions, and Impact of Oxidative Stress in the Disease Process20 September 2022 | ACS Chemical Neuroscience, Vol. 13, No. 19Oxidative Stress and Emergence of Psychosis21 September 2022 | Antioxidants, Vol. 11, No. 10Polypharmacy in Older Adults with Alzheimer’s Disease13 October 2022 | Medicina, Vol. 58, No. 10The alternations of nucleus accumbent in schizophrenia patients with auditory verbal hallucinations during low-frequency rTMS treatment6 September 2022 | Frontiers in Psychiatry, Vol. 13Analysis of color vision and cognitive function in first-episode schizophrenia before and after antipsychotic treatmentJournal of Psychiatric Research, Vol. 152Elevated endogenous GDNF induces altered dopamine signalling in mice and correlates with clinical severity in schizophrenia26 May 2022 | Molecular Psychiatry, Vol. 27, No. 8A novel electrochemical sensor based on thermally reduced graphene oxide for the sensitive determination of dopamineApplied Surface Science, Vol. 592The Relationship Between Frontostriatal Connectivity and Striatal Dopamine Function in Schizophrenia: An 18F-DOPA PET and Diffusion Tensor Imaging Study in Treatment Responsive and Resistant PatientsPsychiatry Investigation, Vol. 19, No. 7Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia11 July 2022 | Metabolomics, Vol. 18, No. 7Bio-Inspired Autonomous Learning Algorithm With Application to Mobile Robot Obstacle Avoidance30 June 2022 | Frontiers in Neuroscience, Vol. 16Graph Convolutional Networks Reveal Network-Level Functional Dysconnectivity in Schizophrenia15 May 2022 | Schizophrenia Bulletin, Vol. 48, No. 4Discours et psychotropesL'Évolution Psychiatrique, Vol. 87, No. 2Ethanol concentration induces production of 3,4-dihydroxyphenylacetic acid and homovanillic acid in mouse brain through activation of monoamine oxidase pathwayNeuroscience Letters, Vol. 782Nanotechnology Approaches for Enhanced CNS Drug Delivery in the Management of Schizophrenia2 October 2021 | Advanced Pharmaceutical Bulletin, Vol. 12, No. 3Aberrant Phase Precession of Lateral Septal Cells in a Maternal Immune Activation Model of Schizophrenia Risk May Disrupt the Integration of Location with Reward8 April 2022 | The Journal of Neuroscience, Vol. 42, No. 20Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trendsNeuroscience & Biobehavioral Reviews, Vol. 136Ketamine enhances dopamine D1 receptor expression by modulating microRNAs in a ketamine-induced schizophrenia-like mouse modelNeurotoxicology and Teratology, Vol. 91It’s About Time: The Circadian Network as Time-Keeper for Cognitive Functioning, Locomotor Activity and Mental Health25 April 2022 | Frontiers in Physiology, Vol. 13Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications22 January 2022 | Pharmacological Reports, Vol. 74, No. 2Activation of D1/D5 receptors ameliorates decreased intrinsic excitability of hippocampal neurons induced by neonatal blockade of N ‐methyl‐ d ‐aspartate receptors4 January 2022 | British Journal of Pharmacology, Vol. 179, No. 8Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D3 Receptors in the Brain in vivo24 March 2022 | Frontiers in Psychiatry, Vol. 13Palladium doped α-MnO2 nanorods on graphene as an electrochemical sensor for simultaneous determination of dopamine and paracetamolApplied Surface Science, Vol. 578Novel D2/5-HT receptor modulators related to cariprazine with potential implication to schizophrenia treatmentEuropean Journal of Medicinal Chemistry, Vol. 232Bottom–Up Evolution of Diamond–Graphite Hybrid Two‐Dimensional Nanostructure: Underlying Picture and Electrochemical Activity11 December 2021 | Small, Vol. 18, No. 8The dual role of dopamine in the modulation of information processing in the prefrontal cortex underlying social behavior22 January 2022 | The FASEB Journal, Vol. 36, No. 2Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders7 February 2022 | Biomedicines, Vol. 10, No. 2The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity29 September 2021 | Neuropsychopharmacology, Vol. 47, No. 3Psychopharmacology: A Brief Overview of Its History5 November 2022Mood Stabilizers: Pharmacology and Biochemistry5 November 2022Antipsychotics/Neuroleptics: Pharmacology and Biochemistry5 November 2022Glutamate, Glutamatergic Drugs and Schizophrenia11 April 2022Known and Unexplored Post-Translational Modification Pathways in Schizophrenia6 August 2022Toxoplasmosis: Targeting neurotransmitter systems in psychiatric disorders3 September 2021 | Metabolic Brain Disease, Vol. 37, No. 1ArylcyclohexaminesAltered central vision and amacrine cells dysfunction as marker of hypodopaminergic activity in treated patients with schizophreniaSchizophrenia Research, Vol. 239The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia29 June 2020 | CNS Spectrums, Vol. 26, No. 6DOPA Homeostasis by Dopamine: A Control-Theoretic View28 November 2021 | International Journal of Molecular Sciences, Vol. 22, No. 23Interaction of Dopamine with Zwitterionic DMPC and Anionic DMPS Multilamellar Vesicle Membranes4 November 2021 | Langmuir, Vol. 37, No. 45The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons12 November 2021 | Frontiers in Molecular Neuroscience, Vol. 14Reactivating a positive feedback loop VTA-BLA-NAc circuit associated with positive experience ameliorates the attenuated reward sensitivity induced by chronic stressNeurobiology of Stress, Vol. 15Humour-based interventions for people with schizophrenia13 October 2021 | Cochrane Database of Systematic Reviews, Vol. 2021, No. 10Localized and Surface Plasmons Coupling for Ultrasensitive Dopamine Detection by means of SPR‐Based Perylene Bisimide/Au Nanostructures Thin Film29 September 2021 | Advanced Materials Interfaces, Vol. 8, No. 20Fast screening test for molecular recognition of levodopa and dopamine in biological samples using 3D printed stochastic microsensorsJournal of Pharmaceutical and Biomedical Analysis, Vol. 205Does nicotine exposure during adolescence modify the course of schizophrenia-like symptoms? Behavioral analysis in a phencyclidine-induced mice model29 September 2021 | PLOS ONE, Vol. 16, No. 9Mechanisms Underlying Motivational Dysfunction in Schizophrenia10 September 2021 | Frontiers in Behavioral Neuroscience, Vol. 15Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats5 June 2021 | Psychopharmacology, Vol. 238, No. 9A New Look on an Old Issue: Comprehensive Review of Neurotransmitter Studies in Cerebrospinal Fluid of Patients with Schizophrenia and Antipsychotic Effect on Monoamine's MetabolismClinical Psychopharmacology and Neuroscience, Vol. 19, No. 3Effects of Radiofrequency Electromagnetic Radiation on Neurotransmitters in the Brain17 August 2021 | Frontiers in Public Health, Vol. 9Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia20 May 2020 | CNS Spectrums, Vol. 26, No. 4A multilayer microfluidic paper coupled with an electrochemical platform developed for sample separation and detection of dopamine1 January 2021 | New Journal of Chemistry, Vol. 45, No. 29Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targetsWorld Journal of Psychiatry, Vol. 11, No. 7History of the dopamine hypothesis of antipsychotic actionWorld Journal of Psychiatry, Vol. 11, No. 7The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies8 July 2021 | Frontiers in Neural Circuits, Vol. 15Perturbations in the catecholamine metabolism and protective effect of “3-(3, 4-dimethoxy phenyl)-1-4(methoxy phenyl) prop-2-en-1-one” during ketamine-induced schizophrenia: an in vivo and in silico studies18 May 2020 | Journal of Biomolecular Structure and Dynamics, Vol. 39, No. 10Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor22 June 2021 | Molecules, Vol. 26, No. 13The role of monoamine oxidase enzymes in the pathophysiology of neurological disordersJournal of Chemical Neuroanatomy, Vol. 114Effect of Neonatal Treatment With the NMDA Receptor Antagonist, MK-801, During Different Temporal Windows of Postnatal Period in Adult Prefrontal Cortical and Hippocampal Function11 June 2021 | Frontiers in Behavioral Neuroscience, Vol. 15Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: a [11C]-(+)-PHNO PET with methylphenidate challenge study5 November 2020 | Molecular Psychiatry, Vol. 26, No. 6Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Sprague–Dawley Rats8 June 2021 | International Journal of Molecular Sciences, Vol. 22, No. 12A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach22 September 2020 | Neuropsychopharmacology, Vol. 46, No. 6Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning28 July 2020 | Neuropsychopharmacology, Vol. 46, No. 6Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease21 April 2021 | International Journal of Molecular Sciences, Vol. 22, No. 9Ultra-sensitive surface enhanced Raman spectroscopy sensor for in-situ monitoring of dopamine release using zipper-like ortho-nanodimersBiosensors and Bioelectronics, Vol. 180Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum1 December 2020 | Schizophrenia Bulletin, Vol. 47, No. 3The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study5 November 2019 | Molecular Psychiatry, Vol. 26, No. 4Automatic and Reliable Quantification of Tonic Dopamine Concentrations In Vivo Using a Novel Probabilistic Inference Method3 March 2021 | ACS Omega, Vol. 6, No. 10Striatal dopamine D 2/3 receptors in medication-naïve schizophrenia: an [ 123 I] IBZM SPECT study8 March 2021 | Psychological Medicine, Vol. 20Association of СОМТ, DRD2/ANKK1, MTHFR, MIR 137, DNMT3B polymorphisms with the clinical features of schizophrenia patients in acute stage and remission25 February 2021 | Doklady of the National Academy of Sciences of Belarus, Vol. 65, No. 1Multi-targeted drug design strategies for the treatment of schizophrenia11 September 2020 | Expert Opinion on Drug Discovery, Vol. 16, No. 1Molecular Imaging in Schizophrenia Spectrum Disorders15 December 2020The Basal Ganglia27 March 2021Antipsychotics/Neuroleptics: Pharmacology and Biochemistry2 September 2021Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies12 June 2020 | Clinical Pharmacokinetics, Vol. 60, No. 1Psychotic disorders, dopaminergic agents and EEG/MEG resting-state functional connectivity: A systematic reviewNeuroscience & Biobehavioral Reviews, Vol. 120Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adultsNeuroscience & Biobehavioral Reviews, Vol. 120Snapshot of Schizophrenia: Current Knowledge and Prospects15 June 2021 | E3S Web of Conferences, Vol. 271Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms16 December 2020 | Pharmacological Reviews, Vol. 73, No. 1Working Memory and Intraindividual Variability in Response Time Mediate Fluid Intelligence Deficits Associated With ADHD Symptomology30 April 2018 | Journal of Attention Disorders, Vol. 25, No. 1Evidence of an interaction between FXR1 and GSK3β polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics19 April 2021 | European Psychiatry, Vol. 64, No. 1Assessment of the Challenges Experienced by Nurses Caring for Patients Diagnosed with Psychotic Disorders in Neuro-Psychiatric Hospitals, from South-West, Nigeria17 August 2021 | African Journal of Health, Nursing and Midwifery, Vol. 4, No. 5Alterations and interactions of subcortical modulatory systems in Alzheimer's diseaseSchizophrenia and Other Psychotic Disorders3 September 2020Dopamine and Response to Antipsychotic Medication15 December 2020Advances in neurochemical measurements: A review of biomarkers and devices for the development of closed-loop deep brain stimulation systems31 December 2020 | Reviews in Analytical Chemistry, Vol. 39, No. 1Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia15 September 2020 | Neurotoxicity Research, Vol. 38, No. 4On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study8 January 2020 | Translational Psychiatry, Vol. 10, No. 1Language disturbances in schizophrenia: the relation with antipsychotic medication7 September 2020 | npj Schizophrenia, Vol. 6, No. 1Post-translational protein modifications in schizophrenia2 March 2020 | npj Schizophrenia, Vol. 6, No. 1Toxoplasma gondii Effects on the Relationship of Kynurenine Pathway Metabolites to Acoustic Startle Latency in Schizophrenia vs. Control Subjects20 November 2020 | Frontiers in Psychiatry, Vol. 11Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients12 November 2020 | Psychopharmacology, Vol. 127Bifunctionalized Prussian blue analogue particles oxidize luminol to produce chemiluminescence without other oxidantsMicrochemical Journal, Vol. 158The role of norepinephrine in the pathophysiology of schizophreniaNeuroscience & Biobehavioral Reviews, Vol. 118Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments5 November 2020 | Pharmaceuticals, Vol. 13, No. 11A meta-analytic approach to mapping co-occurrent grey matter volume increases and decreases in psychiatric disordersNeuroImage, Vol. 222A Split Luciferase Complementation Assay for the Quantification of β-Arrestin2 Recruitment to Dopamine D2-Like Receptors24 August 2020 | International Journal of Molecular Sciences, Vol. 21, No. 17Maternal Immune Activation and the Development of Dopaminergic Neurotransmission of the Offspring: Relevance for Schizophrenia and Other Psychoses21 August 2020 | Frontiers in Psychiatry, Vol. 11Toxoplasmosis and Psychiatric and Neurological Disorders: A Step toward Understanding Parasite Pathogenesis19 June 2019 | ACS Chemical Neuroscience, Vol. 11, No. 16Optimization and tissue distribution of [125I]iododomperidone as a radiotracer for D2-receptor imaging5 June 2020 | Journal of Radioanalytical and Nuclear Chemistry, Vol. 325, No. 2Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiologyNeuropharmacology, Vol. 172Neuromorphological Aspects of the GABAergic Hypothesis of the Pathogenesis of Schizophrenia2 September 2020 | Neuroscience and Behavioral Physiology, Vol. 50, No. 6Conventional and Novel Pharmacological Approaches to Treat Dopamine-Related Disorders: Focus on Parkinson’s Disease and SchizophreniaNeuroscience, Vol. 439The Principle of Nanomaterials Based Surface Plasmon Resonance Biosensors and Its Potential for Dopamine Detection15 June 2020 | Molecules, Vol. 25, No. 12Retinal single-layer analysis with optical coherence tomography (OCT) in schizophrenia spectrum disorderSchizophrenia Research, Vol. 219Effort-based decision making varies by smoking status3 January 2020 | Psychopharmacology, Vol. 237, No. 4A sensitive method to determine dopamine in the presence of uric acid based on In2O3 nanosheet arrays grown on 3D graphene12 March 2020 | Microchimica Acta, Vol. 187, No. 4Perimenstrual psychiatric hospitalization: case report and literature review3 June 2019 | Archives of Women's Mental Health, Vol. 23, No. 2Hospitalization and Some Sociodemographic Characteristics of Patients Registered with a Community Mental Health Center16 November 2019 | Community Mental Health Journal, Vol. 56, No. 3Synthesis and biological investigation of triazolopyridinone derivatives as potential multireceptor atypical antipsychoticsBioorganic & Medicinal Chemistry Letters, Vol. 30, No. 8Intrinsic brain activity of subcortical-cortical sensorimotor system and psychomotor alterations in schizophrenia and bipolar disorder: A preliminary studySchizophrenia Research, Vol. 218A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs21 October 2019 | The Pharmacogenomics Journal, Vol. 20, No. 2Do DSM classifications help or hinder drug development? 1 April 2022 | Dialogues in Clinical Neuroscience, Vol. 22, No. 1Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analysesNeuroImage, Vol. 208Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics27 November 2019 | Neuropsychopharmacology, Vol. 45, No. 4Association of regulatory variants of dopamine β-hydroxylase with cognition and tardive dyskinesia in schizophrenia subjects8 January 2020 | Journal of Psychopharmacology, Vol. 34, No. 3The D2-family receptor agonist bromocriptine but, not nicotine, reverses NMDA receptor antagonist-induced working memory deficits in the radial arm maze in miceNeurobiology of Learning and Memory, Vol. 168Relationship of prolonged acoustic startle latency to diagnosis and biotype in the bipolar-schizophrenia network on intermediate phenotypes (B–SNIP) cohortSchizophrenia Research, Vol. 216Recent Advances in Electrochemical and Optical Sensing of Dopamine14 February 2020 | Sensors, Vol. 20, No. 4Gray Matter Involvement in Schizophrenia: Evidence from Magnetic Resonance Imaging Studies19 February 2020Adult ADHD in Schizophrenia Spectrum and Other Psychotic Disorders23 April 2020Psychopharmacology: A Brief Overview of Its History11 January 2020Mood Stabilizers: Pharmacology and Biochemistry10 June 2020Medical Perspective on Mental Health25 June 2020ASP2905, a specific inhibitor of the potassium channel Kv12.2 encoded by the Kcnh3 gene, is psychoactive in miceBehavioural Brain Research, Vol. 378Early-life exposure to the organophosphorus flame-retardant tris (1,3-dichloro-2-propyl) phosphate induces delayed neurotoxicity associated with DNA methylation in adult zebrafishEnvironment International, Vol. 134Neuropharmacology, Vol. 162Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders5 April 2019 | Molecular Psychiatry, Vol. 25, No. 1Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response20 March 2020 | Schizophrenia Bulletin Open, Vol. 1, No. 1Parvalbumin Interneuron Damage Plays a Central Role in the Pathogenesis of SchizophreniaInternational Journal of Psychiatry and Neurology, Vol. 09, No. 01Region-specific inhibition of 14-3-3 proteins induces psychomotor behaviors in mice14 January 2019 | npj Schizophrenia, Vol. 5, No. 1Marker discovery and associations with β-carotene content in Indian dairy cattle and buffalo breedsJournal of Dairy Science, Vol. 102, No. 11Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to RealityJeffrey A. Lieberman, M.D., Scott A. Small, M.D., Ragy R. Girgis, M.D.1 October 2019 | American Journal of Psychiatry, Vol. 176, No. 10Cerebellar Modulation of Mesolimbic Dopamine Transmission Is Functionally Asymmetrical2 September 2019 | The Cerebellum, Vol. 18, No. 5Functional brain networks in never-treated and treated long-term Ill schizophrenia patients4 June 2019 | Neuropsychopharmacology, Vol. 44, No. 11Designing Functionally Selective Noncatechol Dopamine D 1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity6 August 2019 | ACS Chemical Neuroscience, Vol. 10, No. 9Characterizing fucoxanthin as a selective dopamine D3/D4 receptor agonist: Relevance to Parkinson's diseaseChemico-Biological Interactions, Vol. 310A VTA GABAergic Neural Circuit Mediates Visually Evoked Innate Defensive ResponsesNeuron, Vol. 103, No. 3Serotonin and Glutamate Interactions in Preclinical Schizophrenia Models26 February 2019 | ACS Chemical Neuroscience, Vol. 10, No. 7Bilateral volume reduction in posterior hippocampus in psychosis of epilepsy22 February 2019 | Journal of Neurology, Neurosurgery & Psychiatry, Vol. 90, No. 6Dopamine in psychiatry: a historical perspective13 February 2019 | Journal of Neural Transmission, Vol. 126, No. 4Highly selective and sensitive detection of catecholamines using NaLuGdF4:Yb3+/Er3+ upconversion nanoparticles decorated with metal ionsSensors and Actuators B: Chemical, Vol. 284A Thieno[2,3- d ]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor23 April 2018 | Journal of Medicinal Chemistry, Vol. 62, No. 1Cochrane Database of Systematic ReviewsHippocampusHuman Psychopharmacology: Clinical and Experimental, Vol. 34, No. 2Synapse, Vol. 73, No. 2Paper-Based Electrochemical Biosensors for Point-of-Care Testing of Neurotransmitters18 March 2019 | Journal of Analysis and Testing, Vol. 3, No. 1The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography StudyBiological Psychiatry, Vol. 85, No. 1Neuroscience &